+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06768307

Adebelizumab Combined with Chemotherapy and Radiotherapy Compared Concurrently Versus Sequentially as First Treatment for Extensive-Stage Small Cell Lung Cancer

Led by Peking University Cancer Hospital & Institute · Updated on 2026-08-17

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of adebelizumab combined with chemotherapy and thoracic radiotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer ES-SCLC. This study aims to compare the effectiveness of administering radiotherapy concurrently with immunotherapy and chemotherapy versus sequentially after chemotherapy. The goal is to understand which approach better controls the disease in this advanced lung cancer type. Participants will first receive three cycles of induction therapy with atezolizumab combined with carboplatin or cisplatin plus etoposide chemotherapy. After this, patients without disease progression will move on to either concurrent chemoradiotherapy or sequential chemoradiotherapy combined with atezolizumab. Following these phases, maintenance therapy with atezolizumab alone will continue until disease progression or intolerance, for a maximum of two years. During the study, participants will be monitored through planned visits where treatments, laboratory tests, and other trial procedures will be conducted. Researchers will assess progression-free survival over one year as the primary outcome, with additional evaluations including overall survival up to two years and treatment-related side effects throughout treatment and follow-up. Participants will need to comply with the study schedule, including visits and tests, to help measure the efficacy and safety of the treatment approaches.

CONDITIONS

Brief Title

Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Research Team

R

Rong Yu, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here